| Literature DB >> 32614772 |
Li Zheng1, Xiangjun Chen1, Ting Luo1, Xi Ran1, Jinbo Hu1, Qingfeng Cheng1, Shumin Yang1, Jinshan Wu1, Qifu Li1, Zhihong Wang1,2.
Abstract
INTRODUCTION: Compared with the typical onset of type 2 diabetes in middle age or older, type 2 diabetes with early age of onset has a higher risk of diabetes-related complications. It is unclear whether the early age of diabetes diagnosis would affect the development of end-stage renal disease (ESRD) in patients with diabetic kidney disease (DKD) who are at higher risk of ESRD.Entities:
Mesh:
Year: 2020 PMID: 32614772 PMCID: PMC7367068 DOI: 10.5888/pcd17.200076
Source DB: PubMed Journal: Prev Chronic Dis ISSN: 1545-1151 Impact factor: 2.830
Clinical Characteristics of Patients With Early-Onset and Late-Onset Type 2 Diabetes, The First Affiliated Hospital of Chongqing Medical University, China, 2014–2018
| Characteristic | Overall (N = 1,111) | Onset | ||
|---|---|---|---|---|
| Early (n = 152) | Late (n = 959) |
| ||
| Age, mean (SD), y | 63.6 (10.8) | 48.4 (8.4) | 66 (9.1) | <.001 |
| Age of diabetes onset, mean (SD), y | 52.1 (11.0) | 34.6 (3.8) | 54.9 (9.1) | <.001 |
| Duration of diabetes, mean (SD), y | 11.9 (7.2) | 13.6 (8.0) | 11.6 (7.1) | .001 |
| Male, n (%) | 686 (61.7) | 116 (76.3) | 570 (59.4) | <.001 |
| Hypertension, n (%) | 763 (69.2) | 79 (53.0) | 684 (71.8) | <.001 |
| Smoking, n (%) | 531 (47.8) | 99 (65.1) | 432 (45.0) | <.001 |
| Drinking, n (%) | 436 (39.2) | 86 (56.6) | 350 (36.5) | <.001 |
| Body mass index | 25.1 (3.6) | 25.8 (3.8) | 25.0 (3.6) | .013 |
| Systolic blood pressure, mean (SD), mmHg | 143.7 (22.5) | 140.9 (24.6) | 144.1 (22.1) | .010 |
| Diastolic blood pressure, mean (SD), mmHg | 79.6 (13.6) | 86.6 (13.6) | 78.4 (13.2) | <.001 |
| Total cholesterol, mean (SD), mmol/L | 4.2 (1.3) | 4.5 (1.4) | 4.1 (1.2) | <.001 |
| Total triglyceride, mean (SD), mmol/L | 2.1 (1.9) | 2.7 (2.4) | 2.0 (1.7) | <.001 |
| High density lipoprotein cholesterol, mean (SD), mmol/L | 1.1 (0.4) | 1.0 (0.3) | 1.1 (0.4) | .21 |
| Low density lipoprotein cholesterol, mean (SD), mmol/L | 2.5 (1.1) | 2.7 (1.1) | 2.4 (1.0) | .009 |
| HbA1c, mean (SD), % | 9.1 (2.4) | 9.5 (2.4) | 9.0 (2.4) | .04 |
| Urinary microalbumin creatinine (Cr) ratio, median (interquartile range), mg/g Cr | 194.1 (69.1–753.7) | 221.2 (77.6–1,250.0) | 184.1 (67.2–695.0) | .03 |
| Estimated glomerular filtration rate, mean (SD) | 67.9 (34.6) | 80.3 (43.0) | 66.0 (32.7) | <.001 |
| Oral hypoglycemic drugs, n (%) | 640 (57.6) | 74 (48.7) | 566 (59.0) | .02 |
| Insulin therapy, n (%) | 691 (62.9) | 101 (67.8) | 590 (62.1) | .18 |
| Antihypertensive drugs, n (%) | 672 (61.6) | 72 (48.3) | 600 (63.7) | <.001 |
| RAS blockers, n (%) | 408 (37.4) | 41 (27.5) | 367 (39.0) | .007 |
| Lipid-lowering drugs, n (%) | 216 (19.4) | 22 (14.5) | 194 (20.2) | .11 |
| End stage renal disease, n (%) | 55 (5.0) | 14 (9.2) | 41 (4.3) | .009 |
Abbreviations: CI, confidence interval; HbA1c, glycated hemoglobin; RAS blockers, renin-angiotensin system blockers, including angiotensin converting enzyme inhibitors and angiotensin receptor antagonists.
Data were the effective percentage; the number of patients with missing data has been subtracted from the denominator.
Calculated as weight in kilograms divided by height in meters squared.
FigureAge at diabetes diagnosis in 1,111 patients with or without end-stage renal disease (ESRD), The First Affiliated Hospital of Chongqing Medical University, China, 2014–2018. Circles represent patients; red lines represent mean and standard deviation.
Univariate Logistic Regression Analysis for End Stage Renal Disease in Patients With Diabetic Kidney Disease, The First Affiliated Hospital of Chongqing Medical University, China, 2014–2018
| Variable | Odds Ratio (95% Confidence Interval) |
|
|---|---|---|
| Age, y | 1.00 (0.97–1.02) | .80 |
| Sex, male vs female | 1.00 (0.57–1.75) | .99 |
| Onset, early vs late | 2.27 (1.21–4.28) | .011 |
| Duration of diabetes, y | 1.07 (1.03–1.11) | <.001 |
| History of hypertension | 3.81 (1.62–8.98) | .002 |
| HbA1c, % | 0.72 (0.62–0.85) | <.001 |
| Total cholesterol, mmol/L | 1.09 (0.89–1.33) | .42 |
| Total triglyceride, mmol/L | 0.88 (0.72–1.08) | .22 |
| Low density lipoprotein cholesterol, mmol/L | 1.15 (0.91–1.45) | .26 |
| Systolic blood pressure, mmHg | 1.02 (1.01–1.03) | .001 |
| Diastolic blood pressure, mmHg | 0.99 (0.97–1.01) | .46 |
| Body mass index | 1.01 (0.93–1.09) | .89 |
| Use of oral hypoglycemic drugs | 0.19 (0.10–0.36) | <.001 |
| Use of insulin therapy | 3.16 (1.53–6.53) | .002 |
| Use of antihypertensive drugs | 3.78 (1.76–8.08) | .001 |
| Use of RAS blockers | 0.37 (0.18–0.73) | .005 |
| Use of lipid-lowering drugs | 1.43 (0.76–2.67) | .27 |
Abbreviations: HbA1c, glycated hemoglobin; RAS blockers, renin-angiotensin system blockers, including angiotensin converting enzyme inhibitors and angiotensin receptor antagonists.
Calculated as weight in kilograms divided by height in meters squared.
Odds Ratio of Early-Onset Type 2 Diabetes for End Stage Renal Disease in Patients With Diabetic Kidney Disease, The First Affiliated Hospital of Chongqing Medical University, China, 2014–2018
| Model | Odds Ratio (95% Confidence Interval) |
|
|---|---|---|
| Model 1, early vs late onset | 2.3 (1.2–4.4) | .011 |
| Model 2, early vs late onset | 4.5 (2.0–10.0) | <.001 |
| Model 3, early vs late onset | 4.5 (1.9–10.6) | .001 |
| Model 4, early vs late onset | 3.6 (1.5–8.7) | .005 |
Adjusted for sex.
Further adjusted for traditional metabolic factors, including body mass index, systolic blood pressure, diastolic blood pressure, total cholesterol, total triglyceride, high density lipoprotein cholesterol, low density lipoprotein cholesterol, glycated hemoglobin, smoking history, drinking history, and hypertension history in addition to sex.
Further adjusted for use of oral hypoglycemic drugs, insulin, antihypertensive drugs, renin-angiotensin system blockers (including angiotensin converting enzyme inhibitors and angiotensin receptor antagonists), and lipid-lowering drugs in addition to the variables in model 2.
Further adjusted for the duration of diabetes in addition to the variables in model 3.